Avadel Pharmaceuticals plc(US:AVDL) Xin Lang Cai Jing·2025-11-14 16:17Core Viewpoint - Avadel Pharmaceuticals' stock price surged over 20% following an unsolicited acquisition proposal from Lundbeck, which offers up to $23 per share, surpassing Alkermes' previous offer of $20 per share [1] Company Summary - Avadel Pharmaceuticals' stock reached $23.215 as of the latest report, reflecting a significant market response to the acquisition proposal [1] - The company has not yet determined if Lundbeck's proposal is superior to the existing offer from Alkermes and has not changed its recommendation regarding Alkermes' acquisition plan [1] Industry Summary - The competitive landscape in the pharmaceutical sector is highlighted by the unsolicited bid from Lundbeck, indicating active M&A interest in the sleep medication market [1] - The contrasting offers from Lundbeck and Alkermes illustrate the ongoing strategic maneuvers among companies in the biopharmaceutical industry [1]